Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Obesity often worsens migraine symptoms and increases their frequency and severity. Recent studies indicate that GLP-1 receptor agonists may help in pain modulation. Researchers observed two patients with migraine who began using tirzepatide. This medication is a dual GLP-1 and GIP receptor agonist. After starting tirzepatide, both patients reported fewer migraine headaches. Additionally, they experienced weight loss during the treatment. However, weight loss complicates understanding the medication's direct effect on migraines. The cases highlight the need for further studies on GLP-1 based therapies. These therapies might offer new avenues for migraine management. While initial results seem promising, they remain preliminary. More research is essential to confirm these findings and explore potential mechanisms. Overall, this study opens up possibilities for innovative migraine treatments. Future investigations could clarify the benefits of tirzepatide for those suffering from migraines. Clinical relevance: This research suggests that tirzepatide may offer new hope for migraine treatment.